Abbott (NYSE: ABT) recently reported its Q3 results, with revenues and earnings slightly above our expectations.

Abbott Laboratories, a healthcare giant with diverse divisions, is normalizing post-pandemic as its medical devices drive ...

Abbott (NYSE:ABT) announced today that it launched a new clinical trial to help heart failure patients with advanced therapy ...

Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates for ...

The CEO at the Illinois-based company with operations in Minnesota expects earning to return to a pre-pandemic profit model ...

Medical device giant Abbott Laboratories is launching a $7 billion stock buyback program. The repurchase of common shares was ...

Abbott Laboratories narrowed its full-year profit outlook, raising the midpoint slightly, as strong demand for its diabetes ...

With an in-line performance expected in Q3, ABT stock may trade sideways next week. However, we would watch out for its ...

(Reuters) - Abbott Laboratories slightly lifted its annual profit forecast on Wednesday, after beating Wall Street estimates ...

If a company's history and track record were good enough reasons to buy its shares, it'd be easy to make a case for investing ...

Abbott Laboratories is a diversified healthcare company with strong segments, particularly Medical Devices. Read why I assign ...

Shares of Abbott rose 2% in afternoon trade. The company's medical devices unit generated $4.75 billion in sales for the third quarter, above analysts' average estimate of $4.68 billion ...